A Humoral Immune Response Alters the Distribution of Enzyme Replacement Therapy in Murine Mucopolysaccharidosis Type I.

about

A Humoral Immune Response Alters the Distribution of Enzyme Replacement Therapy in Murine Mucopolysaccharidosis Type I.

Item

http://www.wikidata.org/entity/Q47131823

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

A Humoral Immune Response Alte ...... Mucopolysaccharidosis Type I.

@en

A Humoral Immune Response Alte ...... Mucopolysaccharidosis Type I.

@nl

type

Item

label

A Humoral Immune Response Alte ...... Mucopolysaccharidosis Type I.

@en

A Humoral Immune Response Alte ...... Mucopolysaccharidosis Type I.

@nl

prefLabel

A Humoral Immune Response Alte ...... Mucopolysaccharidosis Type I.

@en

A Humoral Immune Response Alte ...... Mucopolysaccharidosis Type I.

@nl

P1476

A Humoral Immune Response Alte ...... e Mucopolysaccharidosis Type I

@en

P2093

Don Clarke

http://www.w3.org/2001/XMLSchema#string

Kristen N Vondrak

http://www.w3.org/2001/XMLSchema#string

Michelina Iacovino

http://www.w3.org/2001/XMLSchema#string

Moin U Vera

http://www.w3.org/2001/XMLSchema#string

Patricia I Dickson

http://www.w3.org/2001/XMLSchema#string

Shih-Hsin Kan

http://www.w3.org/2001/XMLSchema#string

Steven Q Le

http://www.w3.org/2001/XMLSchema#string

Terence M Doherty

http://www.w3.org/2001/XMLSchema#string

P2860

Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene

Immunogenicity of protein therapeutics

Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I.

Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT.

Biochemical characterization of fluorescent-labeled recombinant human alpha-L-iduronidase in vitro.

Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I.

CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy

Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment

Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I.

Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.

P304

42-51

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.OMTM.2017.09.008

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29159202

http://www.w3.org/2001/XMLSchema#string

P921

Enzyme replacement therapy

P932

5684429

http://www.w3.org/2001/XMLSchema#string